The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...